-
EP4043028
European procedure
- EP About this file
- EP Legal status
- EP Federated register
- EP Event history
- EP Citations
- EP Patent family
- EP All documents
Extract from the Register of European Patents
EP About this file: EP4043028
| EP4043028 - APPLICATION OF PEG-INTERFERON AND PROTOONCOGENE PRODUCT TARGETING INHIBITOR IN SYNERGISTIC INHIBITION OF TUMORS [Right-click to bookmark this link] | Status | Request for examination was made Status updated on 15.07.2022 Database last updated on 15.06.2024 | |
| Former | The international publication has been made Status updated on 10.04.2021 | Most recent event Tooltip | 27.04.2024 | Amendment by applicant | Applicant(s) | For all designated states Shanghai Institute Of Biological Products Co., Ltd 1262 West Yan'an Road Changning District Shanghai 200052 / CN | [2022/33] | Inventor(s) | 01 /
YANG, Yufeng No. 350 Anshun Road, Changning District Shanghai 200051 / CN | 02 /
HE, Cheng No. 350 Anshun Road, Changning District Shanghai 200051 / CN | 03 /
LOU, Jueren No. 350 Anshun Road, Changning District Shanghai 200051 / CN | [2022/33] | Representative(s) | Rondano, Davide Società Italiana Brevetti S.p.A. Via Carducci 8 20123 Milano / IT | [2022/33] | Application number, filing date | 19947849.6 | 31.12.2019 | [2022/33] | WO2019CN130749 | Priority number, date | CN201910943896 | 30.09.2019 Original published format: CN201910943896 | [2022/33] | Filing language | ZH | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2021062961 | Date: | 08.04.2021 | Language: | ZH | [2021/14] | Type: | A1 Application with search report | No.: | EP4043028 | Date: | 17.08.2022 | Language: | EN | [2022/33] | Search report(s) | International search report - published on: | CN | 08.04.2021 | (Supplementary) European search report - dispatched on: | EP | 26.09.2023 | Classification | IPC: | A61K38/21, A61K39/00, C07K17/02, A61P35/00, A61K45/06, A61K47/60, C07K16/32, C07K16/22 | [2023/39] | CPC: |
A61P35/00 (EP,CN,US);
A61K45/06 (EP,CN);
A61K38/212 (CN,US);
A61K38/21 (EP);
A61K39/3955 (EP);
A61K39/39558 (CN);
A61K47/60 (EP);
C07K16/22 (EP);
C07K16/32 (EP);
A61K2039/505 (EP);
A61K2039/54 (EP);
A61K2039/545 (EP);
C07K2317/24 (EP)
(-)
| C-Set: |
A61K38/212, A61K2300/00 (CN);
A61K38/21, A61K2300/00 (EP);
A61K39/39558, A61K2300/00 (CN);
A61K39/3955, A61K2300/00 (EP) |
| Former IPC [2022/33] | A61K38/21, A61K39/00, C07K17/02, A61P35/00 | Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2022/33] | Title | German: | VERWENDUNG VON PEG-INTERFERON UND PROTOONKOGENPRODUKT ALS TARGETING-INHIBITOR IN SYNERGISTISCHER HEMMUNG VON TUMOREN | [2022/33] | English: | APPLICATION OF PEG-INTERFERON AND PROTOONCOGENE PRODUCT TARGETING INHIBITOR IN SYNERGISTIC INHIBITION OF TUMORS | [2022/33] | French: | APPLICATION DE PEG-INTERFÉRON ET D'INHIBITEUR DE CIBLAGE DE PRODUIT PROTO-ONCOGÈNE DANS L'INHIBITION SYNERGIQUE DE TUMEURS | [2022/33] | Entry into regional phase | 29.04.2022 | Translation filed | 29.04.2022 | National basic fee paid | 29.04.2022 | Search fee paid | 29.04.2022 | Designation fee(s) paid | 29.04.2022 | Examination fee paid | Examination procedure | 29.04.2022 | Examination requested [2022/33] | 23.04.2024 | Amendment by applicant (claims and/or description) | 23.04.2024 | Date on which the examining division has become responsible | Fees paid | Renewal fee | 29.04.2022 | Renewal fee patent year 03 | 29.12.2022 | Renewal fee patent year 04 | 28.12.2023 | Renewal fee patent year 05 |
| Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
| Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Documents cited: | Search | [XI]WO2012044684 (BIOGEN IDEC INC [US], et al) [X] 1,3-10 * paragraph [0004] - paragraph [0005] * * example 1 * * paragraph [0006] * * example 2 * * example 3 * * paragraph [0062] * [I] 2; | [XI] - DIWAKAR DAVAR ET AL, "Phase Ib/II Study of Pembrolizumab and Pegylated- Interferon Alfa-2b in Advanced Melanoma", doi:10.1200/JCO, (20181025), URL: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6286160/pdf/JCO.18.00632.pdf, XP093006282 [X] 1,3,7-10 * abstract * [I] 2 DOI: http://dx.doi.org/10.1200/JCO |